| Characteristic |
Stroke patients (n = 18) |
Healthy control subjects (n = 22) |
t or χ2 |
p |
| Age (years) |
70.0 ± 6.7 |
67.2 ± 5.5 |
t=1.46 |
0.15 |
| Female, n (%) |
4 (22.2) |
8 (36.3) |
χ2=0.94 |
0.33 |
| MMSE score |
28.4 ± 1.9 |
29.3 ± 1.0 |
t=1.98 |
0.06 |
| History of disease, n (%) |
| Diabetes mellitus |
5 (27.8) |
2 (9.1) |
χ21=2.40 |
0.12 |
| Hyperlipidemia |
5 (27.8) |
1 (4.5) |
χ21=4.19 |
0.04* |
| Hypertension |
14 (77.8) |
5 (22.7) |
χ21=12.0 |
<0.01** |
| Fazekas DWMH score, n (%) |
| 0–2 |
11 (61.1) |
22 (100) |
|
|
| 3 |
7 (38.9) |
0 (0.0) |
χ2=10.4 |
<0.01** |
| Fazekas PVH score, n (%) |
| 0–2 |
13 (72.2) |
22 (100) |
|
|
| 3 |
5 (27.8) |
0 (0.0) |
χ2=6.98 |
<0.01** |
| mRS score |
1.9 ± 0.7 |
- |
|
|
| NIHSS score |
2.8 ± 0.9 |
- |
|
|
| Anti-coagulant/platelet medication, n (%) |
| Warfarin |
3 (16.7) |
|
|
|
| Acetylsalicylic acid |
13 (72.2) |
|
|
|
| Clopidogrel sulfate |
2 (11.1) |
|
|
|
| Cilostazol |
3 (16.7) |
|
|
|
| Number of acute infarcts |
1.2 ± 0.5 |
- |
|
|
| Volume of acute infarcts (mL) |
1.6 ± 0.9 |
- |
|
|
| Acute infarct location, n (%) |
| Basal ganglia |
11 (61.1) |
- |
|
|
| Subcortical white matter |
6 (33.3) |
|
|
|
| Thalamus |
1 (5.6) |
- |
|
|
| Laterality of acute hemisphere infarcts |
| Left hemisphere, n (%) |
9 (50.0) |
- |
|
|
| Data are the mean ± SD. * p < 0.05, ** p < 0.01; MMSE: Mini-Mental State Examination; DWMH: Deep White Matter Hyperintensity; PVH: Periventricular Hemorrhage; mRS: Modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale |
|
